TScan Therapeutics, Inc. (TCRX) research

TScan Therapeutics, Inc.
ShareXLinkedInReddit
Sector
Biotechnology
Last price
$0.35
As of

TScan Therapeutics, Inc. (TCRX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-11.

As of . Source: SEC EDGAR filings for TCRX. Method and limitations.

SHARE THIS CARD

Share the TCRX intelligence card

A branded snapshot of TCRX: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion TCRX intelligence card preview
Post to X
LIVE TERMINAL

See TCRX live in the terminal

Track TCRX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live TCRX terminal, free

Active signals for TCRX

FREE, NO ACCOUNT

Every signal on TCRX, as it fires

You are seeing 5 of 24 signals recorded on TCRX since 2026-05-30.

The five above landed across 2 days. The other 19 were recorded on 5 other days. 14 of the 24 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in TCRX (2026Q2)

Manager / securityMarket value% portfolioQoQ
TWO SIGMA INVESTMENTS, LPCUSIP 89854M101 · 2026Q2$1.9M0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 89854M101 · 2026Q2$1.3M0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 89854M101 · 2026Q2$1.1M0.00%,
CITADEL ADVISORS LLCCUSIP 89854M101 · 2026Q2$989K0.00%,
D. E. Shaw & Co., Inc.CUSIP 89854M101 · 2026Q2$537K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, TCRX

TCRX mentioned in Kresmion daily briefs

TCRX against its peers

TCRX's operating margin of -1315.4% ranks in the 64th percentile of 6 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.

MetricTCRXPeer medianPercentilen
Revenue FY10.3M USD422849 USD948
Operating margin-1315.4%-1402.2%646
Net margin-1256.8%-1348.8%506
Return on equity-105.4%-89.5%4611

Peers (16): HOTH, CVM, PSTV, GRDX, PVCT, COCP, NXTC, AKTX, ATOS, KYNB, ESLA, BYSI, ABVC, BRNS, QNCX, NEUP. Left out: QNTM (no annual filing), RADX (no annual filing), TTIPF (no annual filing), PLRZ (no annual filing), SEOVF (no annual filing), MDNAF (no annual filing), PBM (period gap), EVAX (no annual filing), IGC (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (TCRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more TCRX signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to TCRXand get the insider, 13F, options, and confluence read in one view.

Open the live TCRX terminal, free